• FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients

    12 days ago - By San Diego Biotechnology

    APD418 currently in Phase 1 clinical investigation - data expected this year
    SAN DIEGO, Jan. 16, 2020 /PRNewswire/ - Arena Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration granted Fast Track des......
    Read more ...